EssilorLuxottica Société anonyme (ESLOY)
OTCMKTS · Delayed Price · Currency is USD
160.76
-1.64 (-1.01%)
Oct 7, 2025, 3:33 PM EDT
ESLOY Revenue
EssilorLuxottica Société anonyme had revenue of 14.02B EUR in the half year ending June 30, 2025, with 9.13% growth. This brings the company's revenue in the last twelve months to 27.24B, up 5.45% year-over-year. In the year 2024, EssilorLuxottica Société anonyme had annual revenue of 26.51B with 4.38% growth.
Revenue (ttm)
27.24B EUR
Revenue Growth
+5.45%
P/S Ratio
4.65
Revenue / Employee
177.47K EUR
Employees
153,498
Market Cap
148.78B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.51B | 1.11B | 4.38% |
Dec 31, 2023 | 25.40B | 901.00M | 3.68% |
Dec 31, 2022 | 24.49B | 4.67B | 23.58% |
Dec 31, 2021 | 19.82B | 5.39B | 37.36% |
Dec 31, 2020 | 14.43B | -2.96B | -17.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |
EssilorLuxottica Société anonyme News
- 1 day ago - EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation - GlobeNewsWire
- 1 day ago - Nikon (NINOF) Shares Climb Amid EssilorLuxottica's Stake Increase - GuruFocus
- 1 day ago - EssilorLuxottica becomes Nikon's largest shareholder, gets clearance to up holding to 20% - Reuters
- 4 days ago - EssilorLuxottica: Neutral Stance Maintained Despite Encouraging Quarter - Seeking Alpha
- 6 days ago - EssilorLuxottica completes acquisition of Optegra - GlobeNewsWire
- 11 days ago - EssilorLuxottica: Essilor Stellest is the first and only FDA market authorized spectacle lens in the United States - GlobeNewsWire
- 19 days ago - EssilorLuxottica: EssilorLuxottica and Meta build on their successful partnership with new AI glasses that offer a glimpse into the future - GlobeNewsWire
- 21 days ago - EssilorLuxottica: Further Outperformance Since 2023 (Rating Downgrade) - Seeking Alpha